These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 26158270)

  • 21. Tracing HIV-1 strains that imprint broadly neutralizing antibody responses.
    Kouyos RD; Rusert P; Kadelka C; Huber M; Marzel A; Ebner H; Schanz M; Liechti T; Friedrich N; Braun DL; Scherrer AU; Weber J; Uhr T; Baumann NS; Leemann C; Kuster H; Chave JP; Cavassini M; Bernasconi E; Hoffmann M; Calmy A; Battegay M; Rauch A; Yerly S; Aubert V; Klimkait T; Böni J; Metzner KJ; Günthard HF; Trkola A;
    Nature; 2018 Sep; 561(7723):406-410. PubMed ID: 30202088
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HIV-1 cell-to-cell transmission and broadly neutralizing antibodies.
    Dufloo J; Bruel T; Schwartz O
    Retrovirology; 2018 Jul; 15(1):51. PubMed ID: 30055632
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quantitative analyses reveal distinct sensitivities of the capture of HIV-1 primary viruses and pseudoviruses to broadly neutralizing antibodies.
    Kim J; Jobe O; Peachman KK; Michael NL; Robb ML; Rao M; Rao VB
    Virology; 2017 Aug; 508():188-198. PubMed ID: 28577855
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HIV Reactivation after Partial Protection by Neutralizing Antibodies.
    Parsons MS; Cromer D; Davenport MP; Kent SJ
    Trends Immunol; 2018 May; 39(5):359-366. PubMed ID: 29366547
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human Ig knockin mice to study the development and regulation of HIV-1 broadly neutralizing antibodies.
    Verkoczy L; Alt FW; Tian M
    Immunol Rev; 2017 Jan; 275(1):89-107. PubMed ID: 28133799
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transmembrane domain membrane proximal external region but not surface unit-directed broadly neutralizing HIV-1 antibodies can restrict dendritic cell-mediated HIV-1 trans-infection.
    Sagar M; Akiyama H; Etemad B; Ramirez N; Freitas I; Gummuluru S
    J Infect Dis; 2012 Apr; 205(8):1248-57. PubMed ID: 22396600
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HIV-1 maternal and infant variants show similar sensitivity to broadly neutralizing antibodies, but sensitivity varies by subtype.
    Mabuka J; Goo L; Omenda MM; Nduati R; Overbaugh J
    AIDS; 2013 Jun; 27(10):1535-44. PubMed ID: 23856624
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reactivation of Neutralized HIV-1 by Dendritic Cells Is Dependent on the Epitope Bound by the Antibody.
    van Montfort T; Thomas AA; Krawczyk PM; Berkhout B; Sanders RW; Paxton WA
    J Immunol; 2015 Oct; 195(8):3759-68. PubMed ID: 26355155
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Conserved Role of an N-Linked Glycan on the Surface Antigen of Human Immunodeficiency Virus Type 1 Modulating Virus Sensitivity to Broadly Neutralizing Antibodies against the Receptor and Coreceptor Binding Sites.
    Townsley S; Li Y; Kozyrev Y; Cleveland B; Hu SL
    J Virol; 2016 Jan; 90(2):829-41. PubMed ID: 26512079
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neutralizing Antibody-Based Prevention of Cell-Associated HIV-1 Infection.
    Parsons MS; Le Grand R; Kent SJ
    Viruses; 2018 Jun; 10(6):. PubMed ID: 29912167
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Broadly neutralizing antibodies: What is needed to move from a rare event in HIV-1 infection to vaccine efficacy?
    Subbaraman H; Schanz M; Trkola A
    Retrovirology; 2018 Jul; 15(1):52. PubMed ID: 30055627
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections.
    Wagh K; Seaman MS; Zingg M; Fitzsimons T; Barouch DH; Burton DR; Connors M; Ho DD; Mascola JR; Nussenzweig MC; Ravetch J; Gautam R; Martin MA; Montefiori DC; Korber B
    PLoS Pathog; 2018 Mar; 14(3):e1006860. PubMed ID: 29505593
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Broadly neutralizing anti-HIV-1 antibodies tether viral particles at the surface of infected cells.
    Dufloo J; Planchais C; Frémont S; Lorin V; Guivel-Benhassine F; Stefic K; Casartelli N; Echard A; Roingeard P; Mouquet H; Schwartz O; Bruel T
    Nat Commun; 2022 Feb; 13(1):630. PubMed ID: 35110562
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Broadly neutralizing antibodies potently inhibit cell-to-cell transmission of semen leukocyte-derived SHIV162P3.
    Suphaphiphat K; Tolazzi M; Hua S; Desjardins D; Lorin V; Dereuddre-Bosquet N; Mouquet H; Scarlatti G; Grand RL; Cavarelli M
    EBioMedicine; 2020 Jul; 57():102842. PubMed ID: 32619962
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Broadly Neutralizing Antibody Responses in a Large Longitudinal Sub-Saharan HIV Primary Infection Cohort.
    Landais E; Huang X; Havenar-Daughton C; Murrell B; Price MA; Wickramasinghe L; Ramos A; Bian CB; Simek M; Allen S; Karita E; Kilembe W; Lakhi S; Inambao M; Kamali A; Sanders EJ; Anzala O; Edward V; Bekker LG; Tang J; Gilmour J; Kosakovsky-Pond SL; Phung P; Wrin T; Crotty S; Godzik A; Poignard P
    PLoS Pathog; 2016 Jan; 12(1):e1005369. PubMed ID: 26766578
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Minimally Mutated HIV-1 Broadly Neutralizing Antibodies to Guide Reductionist Vaccine Design.
    Jardine JG; Sok D; Julien JP; Briney B; Sarkar A; Liang CH; Scherer EA; Henry Dunand CJ; Adachi Y; Diwanji D; Hsueh J; Jones M; Kalyuzhniy O; Kubitz M; Spencer S; Pauthner M; Saye-Francisco KL; Sesterhenn F; Wilson PC; Galloway DM; Stanfield RL; Wilson IA; Burton DR; Schief WR
    PLoS Pathog; 2016 Aug; 12(8):e1005815. PubMed ID: 27560183
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Broadly neutralizing antibodies suppress post-transcytosis HIV-1 infectivity.
    Lorin V; Malbec M; Eden C; Bruel T; Porrot F; Seaman MS; Schwartz O; Mouquet H
    Mucosal Immunol; 2017 May; 10(3):814-826. PubMed ID: 27966557
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The expanding array of HIV broadly neutralizing antibodies.
    McCoy LE
    Retrovirology; 2018 Oct; 15(1):70. PubMed ID: 30326938
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HIV-1-Specific Chimeric Antigen Receptors Based on Broadly Neutralizing Antibodies.
    Ali A; Kitchen SG; Chen ISY; Ng HL; Zack JA; Yang OO
    J Virol; 2016 Aug; 90(15):6999-7006. PubMed ID: 27226366
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neutralizing antibodies for HIV-1 prevention.
    Julg B; Barouch DH
    Curr Opin HIV AIDS; 2019 Jul; 14(4):318-324. PubMed ID: 31082819
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.